The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
Open accessAbstract
BACKGROUND: Interleukin 22 promotes epidermal hyperplasia and inhibits skin barrier function. OBJECTIVE: Evaluate interleukin 22 blockade in adults with moderate-to-severe atopic dermatitis (AD). METHODS: We performed a randomized, double-blind, placebo-controlled trial with intravenous fezakinumab monotherapy every 2 weeks for 10 weeks, with follow-up assessments until 20 weeks. The change in SCOring AD (SCORAD) score from baseline at 12 weeks served as the primary end point. RESULTS: At 12 weeks, the mean declines in SCORAD for the entire study population were 13.8 ± 2.7 in the fezakinumab arm and 8.0 ± 3.1 in the placebo arm (P = .134). In the severe AD patient subset (with a baseline SCORAD of ≥50), SCORAD decline was significantly stronger in the drug-treated patients than placebo-treated patients at 12 weeks (21.6 ± 3.8 vs 9.6 ± 4.2, P = .029) and 20 weeks (27.4 ± 3.9 vs 11.5 ± 5.1, P = .010). At 12 weeks, improvements in body surface area involvement in the entire population were significantly stronger in the drug-treated than placebo-treated patients (12.4% ± 2.4 vs 6.2% ± 2.7; P = .009), and in the severe AD subset, the decline in Investigator Global Assessment was significantly higher in the drug-treated than placebo-treated patients (0.7 ± 0.2 vs 0.3 ± 0.1; P = .034). All scores showed progressive improvements after last dosing (10 weeks) until end of study (20 weeks). Common adverse events were upper respiratory tract infections. LIMITATIONS: The limited sample size and lack of assessment with Eczema Area and Severity Index and a pruritus numerical rating scale were limiting factors. Significance was primarily obtained in severe AD. CONCLUSION: Fezakinumab was well-tolerated, with sustained clinical improvements after last drug dosing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“encouraging results were seen in patients with severe forms (SCORAD >50) where the mean decline in SCORAD was significantly better than in the placebo group122.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [122]
The cited source says what the claim attributes to it.
In the citing paper
“When considering the entire study population, there was no significant difference in the change of SCORAD compared with baseline as the primary end point.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,597
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationWeidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M. H., Bieber, T. R. M., Rocklin, R. E., Ming, J. E., Ren, H., Kao, R., Simpson, E. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,435
Self-citationTh22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling
Eyerich, S., Eyerich, K., Pennino, D., Carbone, T., Nasorri, F., Pallotta, S., Cianfarani, F., Odorisio, T., Traidl-Hoffmann, C., Behrendt, H., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40202 · Cited by 1,052
Self-citationBoniface, K., Bernard, F.-X., Garcia, M., Gurney, A. L., Lecron, J.-C., & Morel, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3695 · Cited by 864
Nograles, K. E., Zaba, L. C., Guttman‐Yassky, E., Fuentes‐Duculan, J., Suárez‐Fariñas, M., Cardinale, I. R., Khatcherian, A., Gonzalez, J., Pierson, K. C., White, T. R., et al. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08769.x · Cited by 816
Self-citationNoda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Self-citationCellular and molecular immunologic mechanisms in patients with atopic dermatitis
Werfel, T., Allam, J., Biedermann, T., Eyerich, K., Gilles, S., Guttman‐Yassky, E., Hoetzenecker, W., Knol, E. F., Simon, H., Wollenberg, A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.010 · Cited by 603
Self-citationAnti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Thaçi, D., Simpson, E. L., Beck, L. A., Bieber, T. R. M., Blauvelt, A., Papp, K. A., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H. L., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 573
Susan, M. L., Valdez, P. A., Wu, J., Jung, K., Zhong, F., Hall, L., Kasman, I. M., Winer, J., Modrusan, Z. D., Danilenko, D. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2229 · Cited by 519
Suárez-Fariñas, M., Dhingra, N., Gittler, J., Shemer, A., Cardinale, I., de Guzman Strong, C., Krueger, J. G., & Guttman-Yassky, E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.046 · Cited by 483
Self-citationHamilton, J. D., Suárez‐Fariñas, M., Dhingra, N., Cardinale, I. R., Li, X., Kostić, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N. M. H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 472
Self-citationEarly-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin
Esaki, H., Brunner, P. M., Renert-Yuval, Y., Czarnowicki, T., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., Johnson, D. B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.013 · Cited by 428
Self-citationPublic Health Burden and Epidemiology of Atopic Dermatitis
Silverberg, J. I. (2017) · Dermatologic Clinics · doi:10.1016/j.det.2017.02.002 · Cited by 400
Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?
Bieber, T. R. M., D’Erme, A. M., Akdiş, C. A., Traidl‐Hoffmann, C., Lauener, R. P., Schäppi, G., & Schmid‐Grendelmeier, P. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.008 · Cited by 329
Self-citationAssessment of clinical signs of atopic dermatitis: A systematic review and recommendation
Schmitt, J. M., Langan, S., Deckert, S., Svensson, Å., von Kobyletzki, L., Thomas, K. S., & Spuls, P. I. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.008 · Cited by 295
Epidemiology of atopic dermatitis: a review
DaVeiga, S. P. (2012) · Allergy and Asthma Proceedings · doi:10.2500/aap.2012.33.3569 · Cited by 236
Boguniewicz, M., Alexis, A. F., Beck, L. A., Block, J. K., Eichenfield, L. F., Fonacier, L. S., Guttman‐Yassky, E., Paller, A. S., Pariser, D. M., Silverberg, J. I., et al. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.08.005 · Cited by 190
Self-citationGalbraith, G. M. P. (2009) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(09)79289-5 · Cited by 167
Lou, H., Lu, J., Choi, E. B., Oh, M. H., Jeong, M., Barmettler, S., Zhu, Z., & Zheng, T. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600126 · Cited by 140
Quality of life and disease severity in patients with atopic dermatitis
Holm, J. G., Agner, T., Clausen, M., & Thomsen, S. F. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13689 · Cited by 121
Atopic dermatitis: Burden of illness, quality of life, and associated complications
Drucker, A. M. (2017) · Allergy and Asthma Proceedings · doi:10.2500/aap.2017.38.4005 · Cited by 108
Bissonnette, R., Poulin, Y., Zhou, Y., Tan, J., Hong, H. C., Webster, J., Ip, W., Tang, L., & Lyle, M. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10775.x · Cited by 92
Pucci, N., Lombardi, E., Novembre, E. M., Fariña, S., Bernardini, R., Rossi, E. M. C., Favilli, T., & VIERUCCI, A. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(00)90087-3 · Cited by 76
Cordoro, K. M., Hitraya‐Low, M., Taravati, K., Sandoval, P. M., Kim, E., Sugarman, J., Pauli, M. L., Liao, W. J., & Rosenblum, M. D. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.05.017 · Cited by 56
Poole, C., Chambers, C., Sidhu, M., & Currie, C. J. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09379.x · Cited by 21
Wollenberg, A., Howell, M. D., Guttman‐Yassky, E., Silverberg, J. I., Birrell, C. E., Kell, C., Ranade, K., Dawson, M., & van der Merwe, R. (2018) · SKIN The Journal of Cutaneous Medicine · doi:10.25251/skin.2.supp.28 · Cited by 18
Self-citationClinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis
Nahm, D., Kim, M., Kwon, B., Cho, S.-M., & Ahn, A. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.6.1420 · Cited by 17
Hon, K. E., Wang, S. S., & Leung, T. F. (2012) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2011.05004.x · Cited by 8
Flagged first, then by citations
2 of the 33 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,141
Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression
Schmiedel, B. J., Singh, D., Madrigal, A., Valdovino-Gonzalez, A. G., White, B. M., Zapardiel-Gonzalo, J., Ha, B., Altay, G., Greenbaum, J. A., McVicker, G., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.022 · Cited by 867
Guttman‐Yassky, E., Bissonnette, R., Ungar, B., Suárez‐Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y. D., Xu, H., Peng, X., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 715
Self-citationAtopic dermatitis endotypes and implications for targeted therapeutics
Czarnowicki, T., He, H., Krueger, J. G., & Guttman‐Yassky, E. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.032 · Cited by 659
Self-citation
Metadata
- Authors
- Guttman-Yassky, E., Brunner, P. M., Neumann, A. U., Khattri, S., Pavel, A. B., Malik, K., Singer, G. K., Baum, D., Gilleaudeau, P., Sullivan-Whalen, M., Rose, S., Jim On, S., Li, X., Fuentes-Duculan, J., Estrada, Y., Garcet, S., Traidl-Hoffmann, C., Krueger, J. G., & Lebwohl, M. G.
- Affiliations
- Rockefeller University (US)
- University of Zurich (CH)
- Icahn School of Medicine at Mount Sinai (US)
- ORCID
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 78
- Issue
- 5
- Pages
- 872-881.e6
- ISSN
- 0190-9622 (ISSN-L)
- PMC
- PMC8711034
- OpenAlex
- W2783616522
- Cited by
- 343
- References
- 33
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 35 · 2023: 40 · 2022: 38 · 2021: 46 · 2020: 49 · 2019: 50 · 2018: 33
- FWCI
- 48.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of the American Academy of Dermatology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
- Site cant be reached (submittedVersion, cc-by-nc-nd)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- OPUS (Augsburg University) (submittedVersion, cc-by-nc-nd)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Celgene
- Danone
- Regeneron Pharmaceuticals
- Dermira
- Glenmark Pharmaceuticals
- Galderma
- LEO Pharma
- National Institutes of Health (UL1TR001866)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (UM1AR063917)
- National Center for Advancing Translational Sciences (UL1TR0001866)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, moderate-to-severe atopic dermatitis, monoclonal antibody therapy, SCORAD, body surface area involvement, upper respiratory tract infection, adverse events, treatment efficacy
- MeSH terms
- Interleukin-22, Adult, Antibodies, Monoclonal, Dermatitis, Atopic, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Interleukins, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
